Mebendazole
Based on 8 publication(s) in Google Scholar
Mebendazole is a highly effective, broad-spectrum antihelmintic against nematode infestations. Mebendazole also exhibits inhibitory effect against glioblastoma multiforme (GBM), inhibits Hedgehog pathway and tubulin polymerization. Mebendazole is orally active and can cross CNS penetration.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.78%
- No. CAS: 31431-39-7
- Fòrmula: C16H13N3O3
- Peso molecular:295.29
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-15310
IvermectinAnti-parasite Agent -
HY-B0413
FenbendazoleAntibiotic -
HY-B0223
AlbendazoleParasiticide -
HY-15142
Doxorubicin hydrochlorideTopoisomerase Inhibitor -
HY-B0294
FlubendazoleTubulin Polymerization Inhibitor -
HY-B0627
MetforminAntihyperglycemic Agent -
HY-B0299
OxibendazolePolymerase Inhibitor -
HY-10221
VorinostatHDAC Inhibitor -
HY-14275
VerapamilCalcium Channel Blocker -
HY-N0488
Vincristine sulfateAntineoplastic Agent -
HY-B0263
Thiabendazolefungicide -
HY-10227
BortezomibProteasome Inhibitor
Publications Citing Use of MedChemExpress (MCE) Mebendazole
More- Adv Sci (Weinh). 2025 Nov 26:e10192. [Abstract]
- EMBO Mol Med. 2025 Jun;17(6):1325-1354. [Abstract]
- Commun Biol. 2024 Jan 24;7(1):123. [Abstract]
- Molecules. 2026 Mar 5;31(5):864. [Abstract]
- Microbiol Spectr. 2026 Mar 17:e0362025. [Abstract]
- PLoS Negl Trop Dis. 2019 Aug 20;13(8):e0007681. [Abstract]
- J Gastroenterol Hepatol. 2024 Dec;39(12):2916-2925. [Abstract]
- Biomed Pharmacother. 2026 Sep:202:119803.
Customer Validation & Images
-
Histological Imaging/Staining
-
Others
Ver todos los productos específicos de isoformas Parasite
More
Actividad biológica
Descripciòn
IC50 & Target
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | EC50 |
0.9 μM
Compound: MBZ
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 29288939] |
| A549/TR | EC50 |
1.7 μM
Compound: MBZ
|
Cytotoxicity against human A549/TR cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human A549/TR cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 29288939] |
| Calu-1 | EC50 |
1.1 μM
Compound: MBZ
|
Cytotoxicity against human Calu1 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human Calu1 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 29288939] |
| HepG2 2.2.15 | IC50 |
>1000 μM
Compound: 5a
|
Antiviral activity against hepatitis B viral in human HepG2.2.15 cells assessed as surface antigen HBsAg secretion after 9 days by ELISA
Antiviral activity against hepatitis B viral in human HepG2.2.15 cells assessed as surface antigen HBsAg secretion after 9 days by ELISA
|
[PMID: 25650312] |
| HepG2 2.2.15 | CC50 |
>1000 μM
Compound: 5a
|
Cytotoxicity against human HepG2.2.15 cells assessed as cell death after 9 days by MTS assay
Cytotoxicity against human HepG2.2.15 cells assessed as cell death after 9 days by MTS assay
|
[PMID: 25650312] |
| HepG2 2.2.15 | IC50 |
>1000 μM
Compound: 5a
|
Antiviral activity against hepatitis B viral in human HepG2.2.15 cells assessed as HBeAg secretion after 9 days by ELISA
Antiviral activity against hepatitis B viral in human HepG2.2.15 cells assessed as HBeAg secretion after 9 days by ELISA
|
[PMID: 25650312] |
| HL-60 | EC50 |
>30 μM
Compound: 1, mebendazole
|
Cytotoxicity against human HL60 cells after 48 to 72 hrs by Alamar blue assay
Cytotoxicity against human HL60 cells after 48 to 72 hrs by Alamar blue assay
|
[PMID: 22795629] |
| HUVEC | IC50 |
8.8 μM
Compound: Mebendazole
|
Inhibition of VEGFR2-mediated angiogenesis in human HUVEC cells after 24 hrs by inverted photomicroscopic analysis
Inhibition of VEGFR2-mediated angiogenesis in human HUVEC cells after 24 hrs by inverted photomicroscopic analysis
|
[PMID: 22780961] |
| NCI-H157 | EC50 |
3.5 μM
Compound: MBZ
|
Cytotoxicity against human NCI-H157 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human NCI-H157 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 29288939] |
| PC-3 | EC50 |
1.1 μM
Compound: MBZ
|
Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 29288939] |
| PC-3M | EC50 |
1.21 μM
Compound: MBZ
|
Cytotoxicity against human PC3M cells assessed as reduction in cell viability after 48 hrs by cyquant reagent based fluorescence spectrometric assay
Cytotoxicity against human PC3M cells assessed as reduction in cell viability after 48 hrs by cyquant reagent based fluorescence spectrometric assay
|
[PMID: 29288939] |
| SK-OV-3 | EC50 |
0.5 μM
Compound: MBZ
|
Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 29288939] |
In Vitro
Mebendazole (1 nM-0.1 mM; 72 h) shows inhibition of GL261 mouse glioma cells with IC50 value of 0.24 μM[1].
Mebendazole (0.1 μM and 1 μM; 24 h) disrupts microtubule polymerization and microtubule structure in 060919 glioblastoma multiforme (GBM) cells[1].
Mebendazole (10 nM-10 μM; 48 h) inhibits Hh signaling and reduces the expression of downstream Hh pathway effectors, by decreasing Gli1 transcript and protein expression in tumor tissues. Mebendazole inhibits Gli1 expression with an IC50 value of 516 nM[2].
Mebendazole (10 nM-10 μM; 48 h) prevents the formation of the primary cilium, and decreases the proliferation and survival of human medulloblastoma cells with constitutive Hh activation[2].
A combination of mebendazole and Vismodegib (HY-10440) achieved additive inhibition of canonical Hh signaling[2].
Mebendazole has effectively treated CNS echinococcosis in numerous clinical settings before, indicating significant CNS penetration property[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
-
Cell Line:Glioblastoma multiforme (GBM) 060919 cells
-
Concentration:1 μM
-
Incubation Time:24 hours
-
Result:Disrupted microtubule structure.
-
Cell Line:DAOY and hTERT-RPE1 cells
-
Concentration:0, 0.1, 0.5, 0.75, and 1 μM
-
Incubation Time:12 hours
-
Result:Decreased GLI1 protein level and increased cleavage of caspase-3 protein level.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 mice (5-6 weeks old) implanted with GL261 glioma cells and 060919 human glioblastoma multiforme (GBM)[1]
-
Dosage:50 mg/kg; delivered with 50% (v/v) sesame oil and PBS[2]
-
Administration:Oral gavage; beginning 5 days after tumor implantation at a daily dose of 50 mg/kg for the first 20 days of treatment then changed to 50 mg/kg for 5 days, with 2 days off, each week.
-
Result:Increased the mean survival to 49 days compared with the 30 days of control in syngeneic GL261 mouse model.
Increased the mean survival to 65 days compared with the 48 days of control in 060919 human glioblastoma multiforme (GBM) xenograft mouse model.
Ensayo clínico
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 31431-39-7
-
Appearance Solid
-
Peso molecular 295.29
-
Fòrmula C16H13N3O3
-
Color Off-white to light yellow
-
SMILES
O=C(OC)NC1=NC2=CC=C(C(C3=CC=CC=C3)=O)C=C2N1
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 1 year -20°C 6 months
Publications (8)
-
Journal Impact Factor
-
Most Recent
-
Adv Sci (Weinh)
Lactylation-Driven YTHDC1 Alleviates MASLD by Suppressing PTPN22-Mediated Dephosphorylation of NLRP3. [Abstract]2025 Nov 26:e10192. PMID: 41298230
Mebendazole purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Nov 26:e10192. [Abstract]
Mebendazole (MBZ: 30,60 mg/kg). Representative images showing morphological changes in the liver. For histopathological studies, liver tissue sections were stained with H&E and Oil red O.
-
EMBO Mol Med
2025 Jun;17(6):1325-1354. PMID: 40295888
Mebendazole purchased from MedChemExpress. Usage Cited in: EMBO Mol Med. 2025 Jun;17(6):1325-1354. [Abstract]
MBZ (Mebendazole) treatment for 48 hours resulted in a dose-dependent decrease in the number of cilia in recurrent GIC. Quantification of fluorescence images after cilia inhibition. Both cell lines were treated with either DMSO alone, 50 nM and 250 nM of MBZ for 48 hours before fixation.
-
Commun Biol
Parbendazole as a promising drug for inducing differentiation of acute myeloid leukemia cells with various subtypes. [Abstract]2024 Jan 24;7(1):123. PMID: 38267545 -
Molecules
2026 Mar 5;31(5):864. PMID: 41828851 -
Microbiol Spectr
Repurposing flufenamic acid as a putative PmrB-directed adjuvant to restore colistin activity in Klebsiella pneumoniae. [Abstract]2026 Mar 17:e0362025. PMID: 41842337 -
PLoS Negl Trop Dis
Identification of anti-flaviviral drugs with mosquitocidal and anti-Zika virus activity in Aedes aegypti. [Abstract]2019 Aug 20;13(8):e0007681. PMID: 31430351 -
J Gastroenterol Hepatol
The m6A reader IGF2BP1 contributes to the activation of hepatic stellate cells through facilitating TUBB4B mRNA stabilization. [Abstract]2024 Dec;39(12):2916-2925. PMID: 39403946 -
Solvente y solubilidad
In Vitro:
DMSO : 4.17 mg/mL (14.12 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 0.42 mg/mL (1.42 mM); Clear solution
This protocol yields a clear solution of ≥ 0.42 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (4.2 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 0.42 mg/mL (1.42 mM); Clear solution
This protocol yields a clear solution of ≥ 0.42 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (4.2 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 5 mg/mL (16.93 mM); Suspended solution; Need ultrasonic
Add each solvent one by one: 15% Cremophor EL 85% Saline
Solubility: 25 mg/mL (84.66 mM); Suspended solution; Need ultrasonic
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (279 KB)
-
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Bai RY, et al. Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme. Neuro Oncol. 2011 Sep;13(9):974-82. [Content Brief]
[2]. Larsen AR, et al. Repurposing the antihelmintic mebendazole as a hedgehog inhibitor. Mol Cancer Ther. 2015 Jan;14(1):3-13. [Content Brief]
[3]. Erdinçler P, et al. The role of mebendazole in the surgical treatment of central nervous system hydatid disease. Br J Neurosurg. 1997 Apr;11(2):116-20. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.3865 mL | 16.9325 mL | 33.8650 mL | 84.6625 mL |
| 5 mM | 0.6773 mL | 3.3865 mL | 6.7730 mL | 16.9325 mL | |
| 10 mM | 0.3387 mL | 1.6933 mL | 3.3865 mL | 8.4663 mL |
Mebendazole Related Classifications
HY-17595 Related Classifications
Powered by Bioz